Janet Kunsman

656 total citations
19 papers, 399 citations indexed

About

Janet Kunsman is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Janet Kunsman has authored 19 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 8 papers in Hematology. Recurrent topics in Janet Kunsman's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Multiple Myeloma Research and Treatments (5 papers). Janet Kunsman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Multiple Myeloma Research and Treatments (5 papers). Janet Kunsman collaborates with scholars based in United States. Janet Kunsman's co-authors include Diane Warren, Irene M. Ghobrial, Stacey Chuma, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Jeffrey Matous, Meghan Rourke, Edie Weller and Brianna Harris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Anesthesiology.

In The Last Decade

Janet Kunsman

18 papers receiving 389 citations

Peers

Countries citing papers authored by Janet Kunsman

Since Specialization

Citations

This map shows the geographic impact of Janet Kunsman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Kunsman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Kunsman more than expected).

Fields of papers citing papers by Janet Kunsman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Kunsman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Kunsman. The network helps show where Janet Kunsman may publish in the future.

Co-authorship network of co-authors of Janet Kunsman

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Kunsman. A scholar is included among the top collaborators of Janet Kunsman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Kunsman. Janet Kunsman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia 2013 ·Blood ·Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, (unknown), Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, (unknown), Diane Warren, Scott J. Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous	37
2	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia 2013 ·Blood ·Steven P. Treon, Christina Tripsas, Kirsten Meid, (unknown), (unknown), Diane Warren, Claudia E. Paba‐Prada, Christopher J. Patterson, Guang Yang, Zachary R. Hunter, Janet Kunsman, Sandra Kanan, Irene M. Ghobrial	9
3	A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia 2013 ·Blood ·Steven P. Treon, Christina Tripsas, Guang Yang, Yang Cao, Lian Xu, Zachary R. Hunter, (unknown), (unknown), Kirsten Meid, Diane Warren, Christopher J. Patterson, Gaurav Varma, Jacob P. Laubach, Claudia E. Paba‐Prada, Janet Kunsman, Irene M. Ghobrial, Sandra Kanan, Ranjana H. Advani, Maria Lia Palomba	35
4	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma 2011 ·Blood ·Irene M. Ghobrial, Ranjit Banwait, Abdel Kareem Azab, Phong Quang, Jacob P. Laubach, Amanda Donovan, (unknown), Philippe Armand, Nikhil C. Munshi, Robert Schlossman, Stacey Chuma, Janet Kunsman, Diane Warren, Kenneth C. Anderson, Paul G. Richardson	7
5	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia 2011 ·Blood ·Irene M. Ghobrial, (unknown), Ranjit Banwait, Tiffany Poon, Amanda Donovan, Stacey Chuma, Janet Kunsman, Diane Warren, (unknown), Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon	2
6	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia 2011 ·Blood ·Irene M. Ghobrial, Ranjit Banwait, Tiffany Poon, Federico Campigotto, (unknown), Stacey Chuma, Janet Kunsman, Amanda Donovan, (unknown), Diane Warren, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Timothy J. Murphy, Jeffrey Matous	2
7	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia 2010 ·American Journal of Hematology ·Irene M. Ghobrial, Wanling Xie, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Tiffany Poon, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous	101
8	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib 2010 ·Blood ·Irene M. Ghobrial, Edie Weller, Ravi Vij, Nikhil C. Munshi, Ranjit Banwait, Meghan Rourke, Robert Schlossman, Jacob P. Laubach, Andrzej Jakubowiak, Renee Leduc, Stacey Chuma, Janet Kunsman, (unknown), Diane Warren, Brianna Harris, Tiffany Poon, Amy Sam, Scott J. Rodig, Kenneth C. Anderson, Paul G. Richardson	5
9	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia 2010 ·Journal of Clinical Oncology ·Irene M. Ghobrial, Fangxin Hong, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous	116
10	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma 2010 ·Blood ·Irene M. Ghobrial, Abdel Kareem Azab, Jacob P. Laubach, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, Robert Schlossman, Stacey Chuma, Janet Kunsman, Diane Warren, Amy Sam, Eric Still, (unknown), Kenneth C. Anderson, Paul G. Richardson	1
11	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia 2010 ·Blood ·Irene M. Ghobrial, Tiffany Poon, Meghan Rourke, Stacey Chuma, Janet Kunsman, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Jeffrey Matous	9
12	Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia 2009 ·Journal of Clinical Oncology ·Irene M. Ghobrial, (unknown), Swaminathan P. Iyer, (unknown), Stacey Chuma, Renee Leduc, Meghan Rourke, Janet Kunsman, Brianna Harris, D Warren, Paul G. Richardson	2
13	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. 2009 ·Blood ·Irene M. Ghobrial, Fangxin Hong, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous	5
14	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia. 2009 ·Blood ·Irene M. Ghobrial, Swaminathan P. Iyer, Ashraf Badros, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Jeffrey Matous	5
15	Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma. 2009 ·Blood ·Irene M. Ghobrial, Ravi Vij, Nikhil C. Munshi, Robert Schlossman, Jacob P. Laubach, Erica Campagnaro, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, (unknown), Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson	9
16	A Prospective Evaluation of Cardiac Risk Index 1984 ·Survey of Anesthesiology ·(unknown), Janet Kunsman, David J. Cullen, David C. Brewster, John H. Tinker	4
17	RESULTS, BENEFITS AND CHARGES FOR INTENSIVE CARE OF THE CRITICALLY ILL PATIENT - UPDATE 1982 1982 ·Anesthesiology ·David J. Cullen, (unknown), Janet Kunsman, D. L. CALDERA, Christine Waternaux	9
18	THE USEFULNESS OF THE GOLDMAN CARDIAC RISK INDEX 1982 ·Anesthesiology ·(unknown), Janet Kunsman, David J. Cullen, David C. Brewster	1
19	Comparison of direct and indirect methods of measuring arterial blood pressure, part II. 1981 ·PubMed ·(unknown), (unknown), Janet Kunsman, (unknown)	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact